symbol |
CMTA |
会社名 | Clementia Pharmaceuticals Inc (クレメンシア・ファ―マシュ―ティカルズ) |
分野(sector) |
Health Care
ヘルスケア
|
産業(industry) |
Major Pharmaceuticals
|
業種 |
バイオテクノロジ―_メディカルリサ―チ
医療関連(Health Care)
|
概要 |
事業概要 Clementia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing disease-modifying treatments for patients suffering from debilitating bone and other diseases with high unmet medical need. Its lead product candidate palovarotene is an oral small molecule that binds and activates retinoic acid receptor gamma (an RARg agonist) and has activity in preventing abnormal new bone formation as well as scar tissue formation (or fibrosis) in a variety of tissues in animal models. It is developing palovarotene for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondroma (MO). Its programs focus on diseases involving tissue transformation via retinoic acid receptors (RARs). The Company also has an eye drop formulation of palovarotene that can potently increase tear production and decrease corneal damage. クレメンシア・ファ―マシュ―ティカルズはカナダのバイオ医薬品企業。臨床段階で、主に骨に関する疾患の治療薬の開発に従事する。同社のリ―ド製品候補であるパロバロテンは、レチノイン酸受容体に結合して活性化する経口小分子で、異常な新生骨の形成ならびに線維症を予防する効果を示す。本社所在地はケベック州モントリオ―ル。 Provides healthcare services
|
本社所在地 | 4150 Sainte-Catherine Street West Suite 550 Montreal Quebec H3Z 2Y5 CAN |
代表者氏名 | David Bonita デビッドボニータ |
代表者役職名 | Chairman of the Board 取締役会会長 |
電話番号 | +1 514-940-3610 |
設立年月日 | 40483 |
市場名 | NASDAQ National Market System |
ipoyear | 2017年 |
従業員数 | 30人 |
url | www.clementiapharma.com |
nasdaq_url | https://www.nasdaq.com/symbol/cmta |
adr_tso | ― |
EBITDA | EBITDA(百万ドル) -46.39424 |
終値(lastsale) | 10.06 |
時価総額(marketcap) | 319078895.04 |
時価総額 | 時価総額(百万ドル) 444.99770 |
売上高 | 売上高(百万ドル) 0.00000 |
企業価値(EV) | 企業価値(EV)(百万ドル) 377.06046 |
当期純利益 | 当期純利益(百万ドル) -74.79327 |
決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Clementia Pharmaceuticals Inc revenues was not reported. Net loss decreased 63% to $24M. Lower net loss reflects Loss on re-measurement at fair value decrease from $48.9M (expense) to $0K Accretion?preferred shares decrease from $2.1M (expense) to $0K Interest income increase from $188K to $1.1M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$2.18 to -$0.76. |